Analytical Considerations When Monitoring Pain Medications by LC-MS/MS | OMICS International | Abstract
ISSN: 2155-9872

Journal of Analytical & Bioanalytical Techniques
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Analytical Considerations When Monitoring Pain Medications by LC-MS/MS

Amadeo Pesce1*, Cameron West1, Robert West1, Sergey Latyshev1, David Masters-Moore1, Patrick Friel2, John M. Hughes2, Perla Almazan1, Elizabeth Gonzales1 and Charles Mikel1

1Millennium Research Institute, San Diego, CA, USA

2Agilent Technologies, Santa Clara, CA, USA

*Corresponding Author:
Amadeo Pesce
Millennium Research Institute, San Diego, CA, USA
E-mail: [email protected]

Received date: May 17, 2012; Accepted date: June 23, 2012; Published date: June 28, 2012

Citation: Pesce A, West C, West R, Latyshev S, Masters-Moore D, et al. (2012) Analytical Considerations When Monitoring Pain Medications by LC-MS/MS. J Anal Bioanal Techniques S5:003. doi: 10.4172/2155-9872.S5-003

Copyright: © 2012 Pesce A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: Laboratory urine drug testing of patients on chronic opioid therapy requires providing a large test menu of medications commonly prescribed for this population as well as metabolites and illicit substances. It has been shown that liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred method to analyze urine specimens for these substances.
Purpose of the study: To describe the challenges and some of the techniques to validate the analytical procedures used to identify and quantify these medications and substances.
Methods: Using data obtained from testing over one million specimens, the authors developed a proposed test menu. Potential isobaric interferences were established by using literature references. A list of potentially interfering medications was obtained by using the proposed test menu and the most commonly prescribed medications. Finally, criteria were designed to detect possible carryover.
Results: The LC-MS/MS instrumentation eliminated all potential interferences and provided quantitative data over the test range needed to monitor these patients. Carryover could be eliminated by setting the carryover thresholds for each analyte.
Conclusions: Reference laboratories utilizing LC-MS/MS technology to conduct urine drug testing for pain clinicians should employ specific techniques described in this study to develop an optimal test menu and validate procedures that include isolating retention times for isobaric compounds, identifying interfering substances including impurities in medicinal and illicit substance preparations, monitoring ion suppression, and avoiding carryover.